These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 19101658)
21. Curcumin activates Wnt/β-catenin signaling pathway through inhibiting the activity of GSK-3β in APPswe transfected SY5Y cells. Zhang X; Yin WK; Shi XD; Li Y Eur J Pharm Sci; 2011 Apr; 42(5):540-6. PubMed ID: 21352912 [TBL] [Abstract][Full Text] [Related]
22. The development of new therapeutics for Alzheimer's disease. Carter MD; Simms GA; Weaver DF Clin Pharmacol Ther; 2010 Oct; 88(4):475-86. PubMed ID: 20811351 [TBL] [Abstract][Full Text] [Related]
23. Sodium selenate activated Wnt/β-catenin signaling and repressed amyloid-β formation in a triple transgenic mouse model of Alzheimer's disease. Jin N; Zhu H; Liang X; Huang W; Xie Q; Xiao P; Ni J; Liu Q Exp Neurol; 2017 Nov; 297():36-49. PubMed ID: 28711506 [TBL] [Abstract][Full Text] [Related]
25. Wnt co-receptor LRP5/6 overexpression confers protection against hydrogen peroxide-induced neurotoxicity and reduces tau phosphorylation in SH-SY5Y cells. Zhang L; Bahety P; Ee PL Neurochem Int; 2015 Aug; 87():13-21. PubMed ID: 25959626 [TBL] [Abstract][Full Text] [Related]
26. Phosphodiesterase 5 inhibitor mirodenafil ameliorates Alzheimer-like pathology and symptoms by multimodal actions. Kang BW; Kim F; Cho JY; Kim S; Rhee J; Choung JJ Alzheimers Res Ther; 2022 Jul; 14(1):92. PubMed ID: 35804462 [TBL] [Abstract][Full Text] [Related]
27. Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein Ser phosphorylation. Jong YJ; Ford SR; Seehra K; Malave VB; Baenziger NL FASEB J; 2003 Dec; 17(15):2319-21. PubMed ID: 14563691 [TBL] [Abstract][Full Text] [Related]
28. Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease. Vallée A; Lecarpentier Y; Guillevin R; Vallée JN Acta Biochim Biophys Sin (Shanghai); 2017 Oct; 49(10):853-866. PubMed ID: 28981597 [TBL] [Abstract][Full Text] [Related]
29. Synaptotoxicity in Alzheimer's disease: the Wnt signaling pathway as a molecular target. Inestrosa NC; Varela-Nallar L; Grabowski CP; Colombres M IUBMB Life; 2007; 59(4-5):316-21. PubMed ID: 17505971 [TBL] [Abstract][Full Text] [Related]
30. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Li HL; Wang HH; Liu SJ; Deng YQ; Zhang YJ; Tian Q; Wang XC; Chen XQ; Yang Y; Zhang JY; Wang Q; Xu H; Liao FF; Wang JZ Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3591-6. PubMed ID: 17360687 [TBL] [Abstract][Full Text] [Related]
31. Wnt/β-catenin signaling in Alzheimer's disease. De Ferrari GV; Avila ME; Medina MA; Perez-Palma E; Bustos BI; Alarcon MA CNS Neurol Disord Drug Targets; 2014; 13(5):745-54. PubMed ID: 24365184 [TBL] [Abstract][Full Text] [Related]
33. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Farías GG; Godoy JA; Vázquez MC; Adani R; Meshulam H; Avila J; Amitai G; Inestrosa NC Neurobiol Dis; 2005 Feb; 18(1):176-83. PubMed ID: 15649708 [TBL] [Abstract][Full Text] [Related]
34. Structure-based design of benzo[e]isoindole-1,3-dione derivatives as selective GSK-3β inhibitors to activate Wnt/β-catenin pathway. Yue H; Lu F; Shen C; Quan JM Bioorg Chem; 2015 Aug; 61():21-7. PubMed ID: 26057861 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Scali C; Caraci F; Gianfriddo M; Diodato E; Roncarati R; Pollio G; Gaviraghi G; Copani A; Nicoletti F; Terstappen GC; Caricasole A Neurobiol Dis; 2006 Nov; 24(2):254-65. PubMed ID: 16919965 [TBL] [Abstract][Full Text] [Related]
36. The revitalized tau hypothesis on Alzheimer's disease. Maccioni RB; Farías G; Morales I; Navarrete L Arch Med Res; 2010 Apr; 41(3):226-31. PubMed ID: 20682182 [TBL] [Abstract][Full Text] [Related]
37. Riluzole: a therapeutic strategy in Alzheimer's disease by targeting the WNT/β-catenin pathway. Vallée A; Vallée JN; Guillevin R; Lecarpentier Y Aging (Albany NY); 2020 Feb; 12(3):3095-3113. PubMed ID: 32035419 [TBL] [Abstract][Full Text] [Related]
38. GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Gao C; Hölscher C; Liu Y; Li L Rev Neurosci; 2011 Dec; 23(1):1-11. PubMed ID: 22718609 [TBL] [Abstract][Full Text] [Related]
39. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. Esposito G; Scuderi C; Lu J; Savani C; De Filippis D; Iuvone T; Steardo L; Sheen V; Steardo L J Cell Mol Med; 2008 Jun; 12(3):914-27. PubMed ID: 18494933 [TBL] [Abstract][Full Text] [Related]
40. Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. Zhang QG; Wang R; Khan M; Mahesh V; Brann DW J Neurosci; 2008 Aug; 28(34):8430-41. PubMed ID: 18716201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]